Assessing the impact of antibiotic therapy on MRSA in hospitalized children
NAsal MEthicillin-resistant Staphylococcus (NAMES): a Prospective Study to Assess the Impact of Antibiotic Therapy on Nasal Colonization with Methicillin-resistant Staphylococcus Aureus (MRSA) in Hospitalized Children
This study is trying to see how antibiotic treatment affects the presence of MRSA in hospitalized children aged 1 to 16 years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 76 (estimated) |
| Ages | 1 Year to 16 Years |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia, Pavia) |
| Trial ID | NCT06872099 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate how antibiotic therapy affects nasal colonization with Methicillin-resistant Staphylococcus Aureus (MRSA) in hospitalized children aged 1 to 16 years. It addresses the growing concern of antimicrobial resistance (AMR) by focusing on the patterns of antibiotic use in pediatric patients, who may respond differently to treatments compared to adults. The study will involve collecting data from children admitted to the hospital, excluding those with specific conditions such as oncologic or hematologic diseases. The goal is to optimize antibiotic usage and reduce unnecessary prescriptions in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are hospitalized children aged between 1 and 16 years who can provide informed consent through their parents or legal guardians.
Not a fit: Patients who may not benefit from this study include those under 1 year old, those with oncologic or hematologic diseases, and those admitted to the Pediatric Intensive Care Unit.
Why it matters
Potential benefit: If successful, this study could lead to improved antibiotic prescribing practices in children, reducing the incidence of MRSA and enhancing patient outcomes.
How similar studies have performed: Other studies have shown success in optimizing antibiotic use in pediatric populations, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: · All the hospitalized children, aged between 1 and 16 years. * Informed consent signed by parents or legal tutors Exclusion Criteria: · All the hospitalized children admitted to the Unit of Oncologic/Hematologic disease or children affected with an hematologic disease also if admitted to the General Paediatric Ward. * All the hospitalized children admitted to the Paediatric Intensive Care Unit (PICU) * All the hospitalized children aged \< 1 years old * Children with parents or legal tutor who eventually refuse to sign the study consent form
Where this trial is running
Pavia, Pavia
- Fondazione IRCCS Policlinico San Matteo, SC Malattie Infettive 1 — Pavia, Pavia, Italy (Recruiting)
Study contacts
- Study coordinator: Alessandra Ricciardi, MD
- Email: a.ricciardi@smatteo.pv.it
- Phone: +390382501543
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.